AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3073045
Drug: Ampicillin or
RxNorm normalized name: ampicillin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin or ampicillin plus chloramphenicol, administered in 4 doses/day for a mean duration of 12.3 days.
Trial: 28163732
Drug: Standard physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard physical therapy
Trial: 27655261
Drug: Financial incentives
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Financial incentives for adherence to antipsychotic depot medication
Trial: 29401355
Drug: Animal-Assisted Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Animal-Assisted Therapy (AAT)
Trial: 24020828
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment protocol
Trial: 23129179
Drug: Orally inhaled
RxNorm normalized name: Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally inhaled allergen
Trial: 23129179
Drug: Orally inhaled
RxNorm normalized name: Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally inhaled diluent placebo
Trial: 17015810
Drug: Second-generation antipsychotics
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-generation antipsychotics (SGAs) other than clozapine
Trial: 19389331
Drug: First-generation antipsychotics
RxNorm normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-generation antipsychotics (FGAs)
Trial: 23602068
Drug: 30 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg intravenous methylprednisolone
Trial: 27604388
Drug: 30 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg intravenous methylprednisolone after anaesthesia induction
Trial: 23250605
Drug: Levodopa/carbidopa (nakom)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa/carbidopa (nakom) treatment in Group 1 (230 patients not previously treated with levodopa)
Trial: 23250605
Drug: Levodopa/carbidopa (nakom)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa/carbidopa (nakom) treatment in Group 2 (262 patients treated with levodopa/carbidopa needing higher doses)
Trial: 23250605
Drug: Levodopa/carbidopa (nakom)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa/carbidopa (nakom) treatment in Group 3 (271 patients treated earlier with other levodopa preparations)
Trial: 19114414
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg valerian (Valeriana officinalis, n = 7)
Trial: 15516023
Drug: Trospium chloride
RxNorm normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trospium chloride oral tablet (20 mg)
Trial: 9828987
Drug: Graded exercise
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Graded exercise and 20 mg fluoxetine
Trial: 9828987
Drug: Appointments and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Appointments and placebo drug
Trial: 1265295
Drug: Intrauterine administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrauterine administration of 5 mg PGF2alpha
Trial: 25846982
Drug: In-person behavior
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In-person behavior therapy
Trial: 21257798
Drug: INCB018424 phosphate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB018424 phosphate, 25 mg bid and 100 mg qd
Trial: 21257798
Drug: Pharmacodynamics of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacodynamics of INCB018424
Trial: 12874502
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg dose of methylphenidate
Trial: 2268938
Drug: Routine drugs
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine drugs only
Trial: 6992827
Drug: Immunotherapy consisting
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy consisting of intradermal BCG plus allogeneic cells
Trial: 20018913
Drug: No maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No maintenance treatment
Trial: 29519541
Drug: Caffeine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (20 mg/kg loading dose followed by 5 mg/kg/day)
Trial: 29519541
Drug: Placebo (blinded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (blinded loading dose of caffeine)
Trial: 30151821
Drug: Apixaban (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban (10 mg twice daily for 7 days followed by 5 mg twice daily thereafter)
Trial: 26623651
Drug: Tilt table
RxNorm normalized name: TILT-123
DrugBank: TILT-123 (DB17519)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tilt table therapy with integrated stepping device (Erigo)
Trial: 24043276
Drug: Intervention (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention (18 1-hour home-based therapy sessions)
Trial: 21373908
Drug: Measured resection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measured resection technique (MG)
Trial: 16406273
Drug: Pethidine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pethidine (100 mg)
Trial: 27543533
Drug: TPVB with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPVB with ropivacaine 0.5%, 25 ml
Trial: 20339099
Drug: Losartan 100
RxNorm normalized name: LOSARTAN 100MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 100 mg/day (LOS)
Trial: 20339099
Drug: Losartan 100
RxNorm normalized name: LOSARTAN 100MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 100 mg/day (LOS) plus Hydrochlorothiazide 25 mg/day (LOS/HCT)
Trial: 18657671
Drug: Sotalol (S)
DrugBank: Sotalol (DB00489)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sotalol (S) 167 ± 66 mg/d
Trial: 18657671
Drug: Beta-blockers (BB)
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers (BB) 62 ± 26 mg/d for atenolol and 104 ± 47 mg/d for metoprolol
Trial: 15668282
Drug: Adjuvant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant treatment (8 cycles of mitoxantrone, methotrexate with tamoxifen)
Trial: 7665721
Drug: Ketorolac 10
RxNorm normalized name: ketorolac 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 10 mg
Trial: 9283163
Drug: Morphine 2
RxNorm normalized name: apomorphine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 2 mg
Trial: 27530980
Drug: Bimanual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimanual therapy (standard practice)
Trial: 25884824
Drug: Smartphone application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smartphone application (SIMPLe) on top of treatment as usual
Trial: 17724363
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg i.v. pantoprazole infused for 15 minutes
Trial: 11157022
Drug: Intensified treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified treatment (ICE every 2 weeks with filgrastim and autologous blood reinfusion)
Trial: 11157022
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (ICE every 4 weeks)
Trial: 9778080
Drug: Front-loaded alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Front-loaded alteplase infusion (100 mg total: 15 mg bolus, then 50 mg over 30 minutes, then 35 mg over 60 minutes)
Trial: 27365387
Drug: Monoclonal antibodies
RxNorm normalized name: Monoclonal antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibodies to C. difficile toxins A and B (not detailed in dosage or duration)
Trial: 24056586
Drug: Balanced crystalloid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced crystalloid (Hartmann's solution)
Trial: 20558112
Drug: Neuropsychological test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuropsychological test battery before antiepileptic treatment
Trial: 18524643
Drug: Foam sclerosant
RxNorm normalized name: SCLEROSING AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foam sclerosant (3% polidocanol foam, 2-2.5 ml injected)
Trial: 18524643
Drug: Liquid sclerosant
RxNorm normalized name: SCLEROSING AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid sclerosant (3% polidocanol liquid, 2-2.5 ml injected)
Trial: 19606472
Drug: Donepezil (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (5-10 mg/day)
Trial: 11153670
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg twice daily
Trial: 1532615
Drug: Ampicillin 500
RxNorm normalized name: ampicillin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin 500 mg four times daily
Trial: 3924399
Drug: Sodium-hydrogen divalproate
RxNorm normalized name: sodium hydrogen sulfite
DrugBank: Sodium bisulfite (DB14015)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium-hydrogen divalproate (SHD) 250 mg
Trial: 3924399
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate 300 mg
Trial: 2905991
Drug: cimetidine 800
RxNorm normalized name: cimetidine 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cimetidine 800 mg
Trial: 24448652
Drug: Omeprazole/sodium bicarbonate
RxNorm normalized name: OMEPRAZOLE/SODIUM BICARBONATE
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole/sodium bicarbonate (Zegerid(®)) 40 mg once daily for 8 weeks (nighttime dosing)
Trial: 19095028
Drug: Live-attenuated influenza
RxNorm normalized name: varicella, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live-attenuated influenza vaccine
Trial: 10189007
Drug: Digitalis 0.75‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digitalis 0.75‐1 mg i.v. plus quinidine 1100 mg (D+Q)
Trial: 2316591
Drug: Amoxicillin treatment
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin treatment for 3 days
Trial: 2316591
Drug: Amoxicillin treatment
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin treatment for 10 days
Trial: 2316591
Drug: Cephalexin or
RxNorm normalized name: cephalexin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin or nitrofurantoin therapy for 7 days (for amoxicillin-resistant infections)
Trial: 20958183
Drug: 1% voriconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% voriconazole (VZ) single dose
Trial: 20958183
Drug: 0.1% voriconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% voriconazole (VZ) single dose
Trial: 20958183
Drug: 1% voriconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% voriconazole (VZ) multidose (hourly)
Trial: 23121439
Drug: Conventional strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional strategy without monitoring and drug adjustment.
Trial: 23121439
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (monitoring and conventional treatment).
Trial: 19758398
Drug: Ondansetron 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 0.2 mg/kg
Trial: 10589108
Drug: Quick Relaxation
RxNorm normalized name: Cal-Quick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quick Relaxation Technique (QRT) in conjunction with analgesics
Trial: 10589108
Drug: Analgesics without
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesics without relaxation exercises
Trial: 30532289
Drug: Inactivated BRSV
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated BRSV vaccine
Trial: 30532289
Drug: Modified-live (MLV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified-live (MLV) BRSV vaccine
Trial: 24495406
Drug: Trazodone 50
RxNorm normalized name: traZODone 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone 50 mg once daily at 10:00 P.M. for 2 weeks
Trial: 16101168
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa 40,000 IU subcutaneously once weekly plus oral iron 200 mg elemental iron once daily
Trial: 16101168
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron 200 mg elemental iron once daily
Trial: 8184044
Drug: Conventional-dose thin-section
RxNorm normalized name: gonorrheal urethral secretion human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-dose thin-section CT (340-mAs)
Trial: 30501868
Drug: Dose-adjusted EPOCH-R
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-adjusted EPOCH-R (DA-EPOCH-R) administered for six cycles with CNS prophylaxis
Trial: 18362256
Drug: New treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New treatments
Trial: 18362256
Drug: Statistically significant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statistically significant trials favoring new or standard treatments
Trial: 10333895
Drug: Baseline ACE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline ACE inhibitor usage
Trial: 31529007
Drug: Behavioral and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral and pelvic floor muscle therapy combined with midurethral sling (n=209)
Trial: 26004044
Drug: Normal exponential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal exponential taper
Trial: 21955196
Drug: Ramelteon 8
RxNorm normalized name: ramelteon 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramelteon 8 mg
Trial: 12923410
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil (8-16 mg once daily)
Trial: 9816717
Drug: 4% lidocaine
RxNorm normalized name: Lidocaine 344 mg TOPICAL PATCH [Pain Relief 4% Lidocaine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% lidocaine 6 ml at room temperature (Group B)
Trial: 9816717
Drug: 4% lidocaine
RxNorm normalized name: Lidocaine 344 mg TOPICAL PATCH [Pain Relief 4% Lidocaine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% lidocaine 5 ml + 7% sodium bicarbonate 1 ml at room temperature (Group C)
Trial: 7621841
Drug: Mianserin 60-90
RxNorm normalized name: mianserin 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mianserin 60-90 mg daily
Trial: 6458872
Drug: Imipramine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (75 mg/day)
Trial: 6458872
Drug: Zimelidine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zimelidine (200 mg/day)
Trial: 6458872
Drug: Zimelidine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zimelidine (100 mg/day)
Trial: 28104096
Drug: Conventional medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional medical treatment (control group)
Trial: 29101117
Drug: Double-dose clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-dose clopidogrel (600 mg day 1; 150 mg days 2-7; then 75 mg daily)
Trial: 20817281
Drug: Double-dose clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-dose clopidogrel
Trial: 19443826
Drug: 12-week twice-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-week twice-weekly heart health program
Trial: 15026868
Drug: Oral alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral alcohol (0.3 g/kg in 250 mL water)
Trial: 15026868
Drug: Intravenous alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alcohol (7.5 mg/kg/minute in 250 mL saline for 40 minutes)
Trial: 15026868
Drug: Control (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (saline 250 mL infused for 40 minutes)
Trial: 15026868
Drug: Both oral
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both oral and intravenous alcohol
Trial: 2572475
Drug: Ketoconazole orally
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoconazole orally (400 mg/day for 5 days)
Trial: 2572475
Drug: Nystatin vaginal
RxNorm normalized name: Nystatin Vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nystatin vaginal pessaries (100,000 units twice/day for 7 days)
Trial: 26151563
Drug: Relief ACP
RxNorm normalized name: Ora Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relief ACP (desensitizing gel)
Trial: 26151563
Drug: UltraEZ (desensitizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UltraEZ (desensitizing gel)
Trial: 26151563
Drug: Control (30-minute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (30-minute treatment without any treatment material)
Trial: 17650536
Drug: Integrated Psychological
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated Psychological Therapy (IPT) program
Trial: 10571597
Drug: Alosetron 1
RxNorm normalized name: alosetron 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alosetron 1 mg twice daily
Trial: 8387963
Drug: Rufloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rufloxacin (400 mg loading dose on day 1, followed by 200 mg s.i.d.)
Trial: 8387963
Drug: Ofloxacin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (300 mg b.i.d.)
Trial: 27391321
Drug: Nurse-coordinated prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-coordinated prevention programme (NCPP) consisting of four outpatient nurse clinic visits in the first 6 months after the index event, focusing on healthy lifestyles, biometric risk factors, and medication adherence, in addition to usual care.
Trial: 15670986
Drug: l-carnitine 990
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-carnitine 990 mg/day + 4 mL/day linseed oil (weeks 5-8)
Trial: 15670986
Drug: 4 mL/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mL/day linseed oil (weeks 1-4)
Trial: 8181137
Drug: Verapamil (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (0.1 mg/kg)
Trial: 10022399
Drug: GnRHa plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRHa plus GH (0.3 mg/kg x week s.c., 6 days weekly, for 2‐4 years)
Trial: 8574277
Drug: Dietary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary treatment (5.0 MJ/day diet) for 16 weeks
Trial: 31634897
Drug: D-cycloserine (DCS)
RxNorm normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D-cycloserine (DCS) 50 mg
Trial: 17667888
Drug: D-cycloserine (DCS)
RxNorm normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D-cycloserine (DCS) 500 mg
Trial: 12814457
Drug: Montelukast 10
RxNorm normalized name: montelukast 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 10 mg daily
Trial: 3630582
Drug: Midazolam 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.05 mg/kg
Trial: 8109230
Drug: Atropine 0.01
RxNorm normalized name: atropine 0.0194 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 0.01 mg/kg
Trial: 11704448
Drug: Midazolam 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.05 mg/kg + Atropine 0.01 mg/kg
Trial: 24991908
Drug: Intervention (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention (24 weekly group sessions led by community care workers)
Trial: 18564693
Drug: Albendazole 400
RxNorm normalized name: albendazole 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole 400 mg twice daily for 7 days
Trial: 11739071
Drug: Animal-assisted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Animal-assisted therapy (AAT) conducted in weekly 4-hour sessions
Trial: 8052779
Drug: High-dose mitomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose mitomycin C plus UFT
Trial: 8052779
Drug: High-dose mitomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose mitomycin C
Trial: 3342553
Drug: Cefazolin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (1 g before surgery, 500 mg every 8 hours for 6 doses)
Trial: 25630840
Drug: Nutritional counselling
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional counselling plus Traditional Chinese Medicine (TCM) acupuncture
Trial: 3895539
Drug: Donor-specific transfusions
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donor-specific transfusions (DST) combined with conventional immunosuppressive therapy (azathioprine, prednisone, and antilymphoblast globulin)
Trial: 29310631
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g CTE in 400 mL of water
Trial: 29310631
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g CTE in 400 mL of water